NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50090-1201-00 | 50090-1201 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 28, 2014 | In Use | |
35356-0197-30 | 35356-0197 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 10, 2010 | Dec 31, 2015 | In Use |
67184-0507-05 | 67184-0507 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 8, 2014 | In Use | |
50090-1414-00 | 50090-1414 | Finasteride | Finasteride | 1.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 28, 2014 | Apr 30, 2016 | No Longer Used |
50090-1600-00 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 5, 2015 | May 31, 2019 | In Use |
50090-1600-05 | 50090-1600 | ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 5, 2015 | Mar 31, 2018 | In Use |
67184-0507-01 | 67184-0507 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 8, 2014 | In Use | |
50090-1718-00 | 50090-1718 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2015 | In Use | |
50090-1718-01 | 50090-1718 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2015 | In Use | |
00591-2222-15 | 00591-2222 | Cyclosporine | Cyclosporine | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Dec 1, 2008 | Dec 31, 2017 | In Use |
50090-1718-02 | 50090-1718 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2015 | In Use | |
00591-2223-15 | 00591-2223 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Dec 1, 2008 | Feb 28, 2018 | In Use |
50090-1892-00 | 50090-1892 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 22, 2015 | Jul 31, 2017 | No Longer Used |
00591-2224-55 | 00591-2224 | Cyclosporine | Cyclosporine | 100.0 mg/mL | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Dec 1, 2008 | Jul 31, 2016 | In Use |
65862-0188-30 | 65862-0188 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
50090-2103-00 | 50090-2103 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 14, 2015 | Jan 31, 2019 | In Use |
16714-0221-12 | 16714-0221 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 29, 2008 | Aug 31, 2021 | No Longer Used |
50090-2103-01 | 50090-2103 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 14, 2015 | Jan 31, 2019 | In Use |
50090-2103-02 | 50090-2103 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 14, 2015 | Jan 31, 2019 | In Use |
50090-2104-00 | 50090-2104 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 14, 2015 | Jan 31, 2019 | In Use |
00591-2292-30 | 00591-2292 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 20, 2015 | Apr 30, 2019 | No Longer Used |
54868-5325-00 | 54868-5325 | Aprepitant | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Jun 24, 2005 | In Use | |||
66220-0110-01 | 66220-0110 | Dexrazoxane Hydrochloride | Totect | 500.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Jul 25, 2017 | Oct 30, 2020 | No Longer Used |
50090-2285-00 | 50090-2285 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 12, 2016 | Dec 31, 2019 | In Use |
51655-0196-80 | 51655-0196 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 20, 2022 | In Use |
Found 11120 results — Export these results